0 seconds of 10 minutes, 5 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
10:05
10:05
 
  • Psyence Group (PSYG) has announced a non-brokered private placement offering of up to $2,000,000 of unsecured convertible promissory notes
  • The notes are convertible to common shares at any time subject to minimum and maximum share prices
  • The notes mature 24 months from their date of issuance and bear an interest rate of 8 per cent per annum
  • Psyence is a public life science biotechnology company focused on natural psychedelics
  • Psysence Group Inc. (PSYG) opened trading at C$0.20 per share

Psyence Group (PSYG) has announced a non-brokered private placement offering of up to $2,000,000 of unsecured convertible promissory notes.

The notes are convertible at any time. The notes will be automatically converted upon the occurrence of certain events at a 20 per cent discount to the market price of the company’s common shares at the time of conversion, subject to a minimum conversion price of $0.25 and a maximum conversion price of $0.40.

The notes mature 24 months from their date of issuance and bear interest at a rate of 8 per cent per annum.

Psyence is a public life science biotechnology company with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Pysence operates one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Lesotho, Southern Africa.

Psysence Group Inc. (PSYG) opened trading at C$0.20 per share.

More From The Market Online
agnes via AMD Telemedicine

UniDoc acquires AGNES Connect software from AMD Telemedicine

UniDoc (CSE:UDOC) acquired the AGNES Connect software from AMD Telemedicine, to expand its NEIL Connect software platform.
Safe Supply Streaming's fentanyl detection strips

Safe Supply Streaming enlists former MP Tony Clement

Safe Supply Streaming (CSE:SPLY) appoints Tony Clement to its board of directors and as chair of its audit committee.
Willow Biosciences logo

Willow Biosciences reports significant loss and imminent closure

Willow Biosciences (TSX:WLLW) reported a net loss of C$6.1 million in 2024, despite achieving a roughly threefold increase in revenue.